Alembic Pharmaceuticals has acquired very last approval from the USA Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5%. The accepted ANDA is therapeutically equivalent to the reference listed drug product (RLD), Timoptic-XE Ophthalmic Gel Forming Solution, zero.25% and 0.Five%, of Bausch Health US, LLC. Timolol Maleate Ophthalmic Gel Forming Solution is indicated inside the remedy of expanded intraocular stress in patients with ocular high blood pressure or open-perspective glaucoma. Alembic has been granted a Competitive Generic Therapies (CGT) designation for this ANDA and it is eligible for 180 days of . CGT exclusivity as it is the primary permitted ANDA.
Timolol Maleate Ophthalmic Gel Forming Solution, zero.25% and zero.Five% has an estimated market size of US$ 71 million for three hundred and sixty five days ending June 2020
in keeping with IQVIA. This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies Pvt Ltd.
Alembic has a cumulative overall of 134 ANDA approvals (117 very last approvals and 17 tentative approvals) from USFDA.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
